RTW Biotech Opportunities (RTW) Share Price, News & Analysis

Company Overview

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Bio is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Key Stats

• Today's Range: 1.19 to 1.20
• 50-Day Range: 1.10 to 1.25
• 52-Week Range: 1.08 to 1.73
• Volume: 27,299 shs
• Average Volume: 250,436 shs
• Market Capitalization: £399.40 million
• P/E Ratio: 2.83
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RTW Stock Analysis - Frequently Asked Questions

How have RTW shares performed this year?

RTW Biotech Opportunities' stock was trading at GBX 1.39 on January 1st, 2025. Since then, RTW stock has decreased by 14.5% and is now trading at GBX 1.19.
View the best growth stocks for 2025 here.

How do I buy shares of RTW Biotech Opportunities?

Shares of RTW stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Financial Services
• Industry: Asset Management
• Sub-Industry: N/A
• Current Symbol: LON:RTW
• CIK: N/A
• Web: www.rtwfunds.com
• Phone: 646-597-6980
• Fax: N/A
• Employees: 4,971
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.42
• Trailing P/E Ratio: 2.83
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £14.09 billion
• Net Margins: 664.38%
• Pretax Margin: N/A
• Return on Equity: 25.18%
• Return on Assets: -0.47%

Debt

• Debt-to-Equity Ratio: 2.27
• Current Ratio: N/A
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: £2.12 billion
• Price / Sales: 0.19
• Cash Flow: GBX 3.69 per share
• Price / Cash Flow: 0.32
• Book Value: GBX 210.25 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 33,591,400,000
• Free Float: N/A
• Market Cap: £399.40 million
• Optionable: Not Optionable
• Beta: 0.60